Next-Gen COVID Vaccines

Our immune response to SARS-CoV-2 centers on the virus’s spike protein. All 3 COVID vaccines authorized in the US are based on a modified version of spike called 2P. A new, more resilient version called HexaPro may be even better.
 
The new design, co-developed by the University of Texas at Austin’s Jason McLellan and colleagues, features not 2 but 6 modifications that lock spike into its pre-weaponized form—fueling infection-fighting antibodies that can neutralize the virus before it invades cells, UT News reports.
 
And, scientists at the Icahn School of Medicine at Mount Sinai have successfully cultured harmless HexaPro-covered viruses in chicken eggs, The New York Times reports. The resulting vaccine, NDV-HXP-S, is now entering clinical trials in Vietnam, Thailand, Brazil, and Mexico.
 
If safe and effective, NDV-HXP-S could be cheaply manufactured using existing factories many countries already use to make flu shots—which could allow many LMICs to make NDV-HXP-S themselves.
 

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top